Sesen Bio (Sesen Bio) Construction In Progress : $0.00 Mil (As of Dec. 2022)

View and export this data going back to 2014. Start your Free Trial

What is Sesen Bio Construction In Progress?

Sesen Bio Construction In Progress Historical Data

The historical data trend for Sesen Bio's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sesen Bio Construction In Progress Chart

Sesen Bio Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Construction In Progress

Get a 7-Day Free Trial

Sesen Bio Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Construction In Progress	Get a 7-Day Free Trial															-	-	-	-	-

Sesen Bio Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

Sesen Bio (Sesen Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sesen Bio Inc (NAS:SESN) » Definitions » Construction In Progress

Comparable Companies

Traded in Other Exchanges

N/A

Address

245 First Street, Suite 1800, Cambridge, MA, USA, 02142

Website

https://www.sesenbio.com

Sesen Bio Inc is a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer. The company's product candidate, Vicineum, also known as VB4-845, is a locally-administered targeted fusion protein composed of an anti-epithelial cell adhesion molecule antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG.

Executives

Modernatx, Inc.	10 percent owner	200 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Sanford S Zweifach	director	21720 23RD DRIVE SE, SUITE 150, BOTHELL WA 98021
Steven Kelly	director, officer: President and CEO	C/O INNOVIVE PHARMACEUTICALS, INC., 555 MADISON AVENUE, 25TH FLOOR, NEW YORK NY 10022
Briggs Morrison	director	C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD, SUITE 110, WALTHAM MA 02451
Richard Steven Morris	officer: Chief Financial Officer	397 EAGLEVIEW BOULEVARD, EXTON PA 19341
Chidozie Ugwumba	director	158 FILMORE STREET, DENVER CO 80206
Bjorn Odlander	director	C/O ODLANDER, FREDRIKSON & CO. AB, STRANDVAGEN 5B, STOCKHOLM V7 SE-114 51
Michael Klichinsky	officer: Chief Scientific Officer	C/O CARISMA THERAPEUTICS INC., 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Michael Torok	director	C/O CARISMA THERAPEUTICS INC., 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Regina Hodits	director	C/O CARISMA THERAPEUTICS INC., 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Elly Ryu	officer: Principal Accounting Officer	245 FIRST STREET, SUITE 1800, CAMBRIDGE MA 02142
Glen C Macdonald	officer: Chief Technology Officer	245 FIRST STREET, SUITE 1800, CAMBRIDGE MA 02142
Monica Forbes	officer: Chief Financial Officer	3344 NORTH TORREY PINES CT., SUITE 200, SAN DIEGO CA 92037
Thomas R Cannell	director, officer: President and CEO	C/O SESEN BIO, INC., 245 FIRST STREET, SUITE 1800, CAMBRIDGE MA 02142
Mark Sullivan	officer: General Counsel & Secretary	1000 BISHOPS GATE BOULEVARD, SUITE 300, MOUNT LAUREL NJ 08054